Cargando…

Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives

Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high morbidity and mortality; indeed the majority...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristaldi, Marta, Mauceri, Rodolfo, Di Fede, Olga, Giuliana, Giovanna, Campisi, Giuseppina, Panzarella, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6914830/
https://www.ncbi.nlm.nih.gov/pubmed/31920689
http://dx.doi.org/10.3389/fphys.2019.01476
_version_ 1783479891125075968
author Cristaldi, Marta
Mauceri, Rodolfo
Di Fede, Olga
Giuliana, Giovanna
Campisi, Giuseppina
Panzarella, Vera
author_facet Cristaldi, Marta
Mauceri, Rodolfo
Di Fede, Olga
Giuliana, Giovanna
Campisi, Giuseppina
Panzarella, Vera
author_sort Cristaldi, Marta
collection PubMed
description Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high morbidity and mortality; indeed the majority of OSCC has been lately identified in the advanced clinical stage (i.e., III or IV). Moreover, after primary treatment, recurrences and/or metastases are found in more than half of the patients (80% of cases within the first 2 years) and the 5-year survival rate is still lower than 50%, resulting in a serious issue for public health. Currently, histological investigation represents the “gold standard” of OSCC diagnosis; however, recent studies have evaluated the potential use of non-invasive methods, such as “liquid biopsy,” for the detection of diagnostic and prognostic biomarkers in body fluids of oral cancer patients. Saliva is a biofluid containing factors such as cytokines, DNA and RNA molecules, circulating and tissue-derived cells, and extracellular vesicles (EVs) that may be used as biomarkers; their analysis may give us useful information to do early diagnosis of OSCC and improve the prognosis. Therefore, the aim of this review is reporting the most recent data on saliva biomarker detection in saliva liquid biopsy from oral cancer patients, with particular attention to circulating tumor DNA (ctDNA), EVs, and microRNAs (miRNAs). Our results highlight that saliva liquid biopsy has several promising clinical uses in OSCC management; it is painless, accessible, and low cost and represents a very helpful source of diagnostic and prognostic biomarker detection. Even if standardized protocols for isolation, characterization, and evaluation are needed, recent data suggest that saliva may be successfully included in future clinical diagnostic processes, with a considerable impact on early treatment strategies and a favorable outcome.
format Online
Article
Text
id pubmed-6914830
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69148302020-01-09 Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives Cristaldi, Marta Mauceri, Rodolfo Di Fede, Olga Giuliana, Giovanna Campisi, Giuseppina Panzarella, Vera Front Physiol Physiology Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high morbidity and mortality; indeed the majority of OSCC has been lately identified in the advanced clinical stage (i.e., III or IV). Moreover, after primary treatment, recurrences and/or metastases are found in more than half of the patients (80% of cases within the first 2 years) and the 5-year survival rate is still lower than 50%, resulting in a serious issue for public health. Currently, histological investigation represents the “gold standard” of OSCC diagnosis; however, recent studies have evaluated the potential use of non-invasive methods, such as “liquid biopsy,” for the detection of diagnostic and prognostic biomarkers in body fluids of oral cancer patients. Saliva is a biofluid containing factors such as cytokines, DNA and RNA molecules, circulating and tissue-derived cells, and extracellular vesicles (EVs) that may be used as biomarkers; their analysis may give us useful information to do early diagnosis of OSCC and improve the prognosis. Therefore, the aim of this review is reporting the most recent data on saliva biomarker detection in saliva liquid biopsy from oral cancer patients, with particular attention to circulating tumor DNA (ctDNA), EVs, and microRNAs (miRNAs). Our results highlight that saliva liquid biopsy has several promising clinical uses in OSCC management; it is painless, accessible, and low cost and represents a very helpful source of diagnostic and prognostic biomarker detection. Even if standardized protocols for isolation, characterization, and evaluation are needed, recent data suggest that saliva may be successfully included in future clinical diagnostic processes, with a considerable impact on early treatment strategies and a favorable outcome. Frontiers Media S.A. 2019-12-10 /pmc/articles/PMC6914830/ /pubmed/31920689 http://dx.doi.org/10.3389/fphys.2019.01476 Text en Copyright © 2019 Cristaldi, Mauceri, Di Fede, Giuliana, Campisi and Panzarella. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Cristaldi, Marta
Mauceri, Rodolfo
Di Fede, Olga
Giuliana, Giovanna
Campisi, Giuseppina
Panzarella, Vera
Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives
title Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives
title_full Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives
title_fullStr Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives
title_full_unstemmed Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives
title_short Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives
title_sort salivary biomarkers for oral squamous cell carcinoma diagnosis and follow-up: current status and perspectives
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6914830/
https://www.ncbi.nlm.nih.gov/pubmed/31920689
http://dx.doi.org/10.3389/fphys.2019.01476
work_keys_str_mv AT cristaldimarta salivarybiomarkersfororalsquamouscellcarcinomadiagnosisandfollowupcurrentstatusandperspectives
AT maucerirodolfo salivarybiomarkersfororalsquamouscellcarcinomadiagnosisandfollowupcurrentstatusandperspectives
AT difedeolga salivarybiomarkersfororalsquamouscellcarcinomadiagnosisandfollowupcurrentstatusandperspectives
AT giulianagiovanna salivarybiomarkersfororalsquamouscellcarcinomadiagnosisandfollowupcurrentstatusandperspectives
AT campisigiuseppina salivarybiomarkersfororalsquamouscellcarcinomadiagnosisandfollowupcurrentstatusandperspectives
AT panzarellavera salivarybiomarkersfororalsquamouscellcarcinomadiagnosisandfollowupcurrentstatusandperspectives